Stockscreener 앱 받기
38.30
5.77%
2.09
시간 외 거래:
38.30
전일 마감가:
$36.21
열려 있는:
$37.41
하루 거래량:
68,381
Relative Volume:
1.79
시가총액:
$150.85M
수익:
$17,000
순이익/손실:
$-31.08M
주가수익비율:
-11.45
EPS:
-3.3463
순현금흐름:
$-24.86M
1주 성능:
+5.51%
1개월 성능:
-0.56%
6개월 성능:
+67.92%
1년 성능:
+122.67%
1일 변동 폭
$37.35
$39.00
1주일 범위
$34.20
$39.20
52주 변동 폭
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
명칭
Vtv Therapeutics Inc
전화
336-841-0300
주소
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
38.30 | 142.62M | 17,000 | -31.08M | -24.86M | -3.3463 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 개시 | Evercore ISI | Outperform |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2026-01-05 | 개시 | TD Cowen | Buy |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2019-05-30 | 개시 | H.C. Wainwright | Buy |
| 2018-04-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 개시 | Northland Capital | Outperform |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2015-09-04 | 개시 | Canaccord Genuity | Buy |
| 2015-08-24 | 개시 | Piper Jaffray | Overweight |
| 2015-08-24 | 개시 | Stifel | Buy |
모두보기
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
How CRH plc stock performs during market volatility - baoquankhu1.vn
Aug Action: Does vTv Therapeutics Inc have declining or rising EPSEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Moves: Is vTv Therapeutics Inc exposed to currency risks2026 Key Highlights & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (VTVT) - Stock Traders Daily
Guidance Update: Will vTv Therapeutics Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
Published on: 2026-03-23 05:09:08 - baoquankhu1.vn
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
VTV Therapeutics (VTVT) reports $27M 2025 net loss amid cadisegliatin advancements - MSN
VTVT Forecast, Price Target & Analyst Ratings | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements - Yahoo Finance
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade - Yahoo Finance
vTv Therapeutics to Participate in the 38th Annual ROTH Conference - The Manila Times
VTv Therapeutics to Participate in the 38th Annual ROTH Conference - marketscreener.com
Biotech developing oral type 1 diabetes drug joins ROTH investor event - Stock Titan
Baker BROS. Advisors LP Has $3.46 Million Holdings in vTv Therapeutics Inc. $VTVT - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Evercore - MarketBeat
Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to "Hold" - MarketBeat
HC Wainwright Raises Earnings Estimates for vTv Therapeutics - Defense World
HC Wainwright Brokers Increase Earnings Estimates for VTVT - Defense World
HC Wainwright Forecasts Higher Earnings for vTv Therapeutics - MarketBeat
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Oxford BioMedica (OtherOXBDF) - The Globe and Mail
Evercore ISI initiates vTv Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Evercore ISI Initiates vTv Therapeutics at Outperform With $44 Price Target - marketscreener.com
Evercore ISI Initiates Coverage on VTVT with Outperform Rating | VTVT Stock News - GuruFocus
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Research Analysts Set Expectations for VTVT Q1 Earnings - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving AverageShould You Sell? - MarketBeat
vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday - MarketBeat
Avoiding Lag: Real-Time Signals in (VTVT) Movement - Stock Traders Daily
BTIG Maintains Buy on vTv Therapeutics Inc (VTVT) March 11, 2026 - Meyka
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained By Investing.com - Investing.com Canada
VTVT: BTIG Reiterates Buy Rating with Unchanged Price Target | V - GuruFocus
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained - Investing.com
vTv Therapeutics 2025 – Pipeline, Clinical Trials, and Patent Portfolio Overview - Minichart
vTv Therapeutics price target raised to $55 from $35 at Alliance Global - TipRanks
VTv Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway - TipRanks
vTv Therapeutics 2025 10-K: $0.0M Revenue, $(26.97)M Net Loss - TradingView
VTv Therapeutics: Fourth Quarter Earnings Overview - Bitget
vTv Therapeutics Inc 預計每股虧損 81 美分財報前瞻 - TradingView
VTV Therapeutics (VTVT) Quarterly & Annual Financial Results 2026News and Statistics - IndexBox
vTv Therapeutics (NASDAQ: VTVT) highlights cadisegliatin Phase 3 and new funding - Stock Titan
VTVT Stock Bolstered by Strong Financials and Strategic Advances - GuruFocus
vTv Therapeutics (VTVT) spotlights Phase 3 cadisegliatin and cash runway - Stock Titan
vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09) - TipRanks
vTv Therapeutics (VTVT) boosts cash, advances Phase 3 CATT1 trial - Stock Titan
vTv Therapeutics Q4 net loss widens on higher expenses - TradingView
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Weekly Voice
Vtv Therapeutics: Capital Efficiency and Clinical Catalysts Under Scrutiny - AD HOC NEWS
Aug Shorts: Will vTv Therapeutics Inc outperform the market in YEAREarnings Risk Report & Verified Technical Trade Signals - baoquankhu1.vn
Vtv Therapeutics Inc (VTVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):